Kineta Inc is a biotechnology company that was founded in 2007 and is headquartered in Seattle, Washington, USA. The company is focused on developing novel therapies for autoimmune and viral diseases, as well as immuno-oncology drugs that harness the immune system to fight cancer.
Kineta's drug development platform is based on its proprietary technology, called Immune Modulation and Drug Delivery (IMDD), which is designed to target specific cells and tissues in the body with high precision. The company is currently working on a number of drug candidates, including:
KCP506 - a drug candidate for the treatment of chronic pain that targets the KCNQ2/3 ion channel.
KVA12.1 - a drug candidate for the treatment of autoimmune diseases that targets the KV1.3 ion channel.
RIG-I Agonists - a class of drugs that stimulate the innate immune system to fight viral infections, including COVID-19.
In addition to its drug development programs, Kineta also provides contract research services to other biotechnology companies and academic institutions, with a focus on developing new drugs and technologies for the treatment of various diseases.
Kineta is a privately held company and has raised significant funding from a variety of sources, including venture capital firms and government grants. The company has also formed strategic partnerships with other biotechnology companies and academic institutions to advance its drug development programs.
|
